Fund Iv, L.P.Omega Fund Iv ... Net Worth

The estimated Net Worth of Fund Iv, L.P.Omega Fund Iv ... is at least 2.77 百万$ dollars as of 19 July 2018. Fund Iv owns over 266,667 units of Replimune Inc stock worth over 2,765,337$ and over the last 6 years Fund sold REPL stock worth over 0$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Fund Iv REPL stock SEC Form 4 insiders trading

Fund has made over 1 trades of the Replimune Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Fund bought 266,667 units of REPL stock worth 4,000,005$ on 19 July 2018.

The largest trade Fund's ever made was buying 266,667 units of Replimune Inc stock on 19 July 2018 worth over 4,000,005$. On average, Fund trades about 88,889 units every 0 days since 2018. As of 19 July 2018 Fund still owns at least 266,667 units of Replimune Inc stock.

You can see the complete history of Fund Iv stock trades at the bottom of the page.

What's Fund Iv's mailing address?

Fund's mailing address filed with the SEC is 185 Dartmouth St Suite 160, Boston, MA 02116, USA.

Insiders trading at Replimune Inc

Over the last 6 years, insiders at Replimune Inc have traded over 72,652,546$ worth of Replimune Inc stock and bought 2,360,000 units worth 33,565,200$ . The most active insiders traders include Group, Llc Green Jeremy Red...、Capital Life Sciences Inves...、Jason P Rhodes. On average, Replimune Inc executives and independent directors trade stock every 21 days with the average trade being worth of 508,649$. The most recent stock trade was executed by Emily Luisa Hill on 16 August 2024, trading 8,938 units of REPL stock currently worth 90,989$.

What does Replimune Inc do?

replimune group, inc., a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. it uses its proprietary immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. the company's lead product candidate is rp1, a selectively replicating version of herpes simplex virus 1, which is in phase i/ii clinical trials for a range of solid tumors; and that is in phase ii clinical trials for patients with cutaneous squamous cell carcinoma. it is also developing rp2, which is in phase i clinical trials for an anti-ctla-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by ctla-4; and rp3 to express immune-activating proteins that stimulate t cells. replimune group, inc. was founded in 2015 and is headquartered in woburn, massachusetts.

Complete history of Fund Iv stock trades at Kezar Life Sciences Inc、Replimune Inc

Replimune Inc executives and stock owners

Replimune Inc executives and other stock owners filed with the SEC include:

• Pradeep Misra,
  Chairman of the Board, Managing Director
• Richa Misra,
  Whole-time Director
• Philip Astley-Sparke FSA,
  CEO & Director
• Dr. Robert Coffin Ph.D.,
  Founder, Pres, Chief R&D Officer and Director
• Philip Astley-Sparke,
  CEO & Director
• Vikas Gupta,
  Company Secretary and Compliance Officer
• Manoj Kumar,
  Chief Financial Officer
• Tanya N. Lewis M.S.,
  Chief Devel. Operations Officer
• Tarun Jain,
  Non-Executive Independent Director
• Himanshu Garg,
  Non-Executive Independent Director
• Jamal Ansari,
  Non-Executive Independent Director
• Dr. Colin A. Love Ph.D.,
  Chief Operating Officer
• Sushil Patel Ph.D.,
  Chief Commercial Officer
• Dr. Pamela Esposito Ph.D.,
  Chief Bus. Officer
• Dr. Colin A. Love,
  Chief Operating Officer
• Jean M. Franchi,
  Principal Accounting Officer, CFO, Treasurer, Sec. & Compliance Officer
• Robert Coffin,
  Director
• Veleka Peeples Dyer,
  Director
• Dieter Weinand,
  Director
• Howard Kaufman,
  Chief Medical Officer
• Stephen A Gorgol,
  Chief Accounting Officer
• Colin Love,
  Chief Operating Officer
• Capital Fund Iii Cooperatie...,
  10% owner
• Hugo Alexander Slootweg,
  Director
• Group, Llc Green Jeremy Red...,
  
• Kapil Dhingra,
  Director
• Venture Fund X, L.P.Atlas V...,
  
• Hyam Levitsky,
  Director
• Pamela Esposito,
  Chief Business Officer
• Jason P Rhodes,
  Director
• Joseph P Slattery,
  Director
• Capital Life Sciences Inves...,
  
• Fund Iv, L.P.Omega Fund Iv ...,
  
• Philip Astley Sparke,
  Executive Chairman
• Paolo Pucci,
  Director
• Venture Fund X, L.P. Atlas,
  10% owner
• Fund Iv, L.P.Omega Fund Iv ...,
  
• Fund Iv, L.P.Omega Fund Iv ...,
  
• Jean M. Franchi,
  Chief Financial Officer
• Emily Luisa Hill,
  Chief Financial Officer
• Konstantinos Xynos,
  Chief Medical Officer
• Andrea Pirzkall,
  Chief Medical Officer
• Christy J. Oliger,
  Director
• Tanya Lewis,
  Chief Dev. Op. Officer
• Sushil Patel,
  Chief Executive Officer
• Christopher Sarchi,
  Chief Commercial Officer
• Andrew Schwendenman,
  Chief Accounting Officer